Heart Rhythm

Hearts should have normal rhythm to their beats, but when these beats are out of synch, it causes inefficient pumping of blood. Irregular heart arrhythmias occur when the electrical signals that coordinate the heart's beats do not work properly. This can cause beats that are too fast (tachycardia), or too slow (bradycardia). Tachycardias include atrial fibrillation (AFib), supraventricular tachycardia, ventricular fibrillation, and ventricular tachycardia (VT). Bradycardias include sick sinus syndrome and conduction block. Electrophysiology arrhythmia treatments include medications, life style changes, and the EP lab interventions of catheter ablation, and implantable pacemakers or defibrillators.

Universal heart screening for all athletes? Not so fast, cardiologists warn
Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences.
New heart catheter for cell therapy delivery 1 step closer to FDA approval
The BioCardia delivery catheter was designed to be used by interventional cardiologists, electrophysiologists or cardiac surgeons. It includes a tiny needle that directly engages with the patient’s cardiac tissue.
Reprocessed EP catheters recalled due to contamination risk
The FDA has announced seven Class I recalls related to this issue. Customers are urged to destroy the devices immediately instead of returning them to the manufacturer.
ECG market keeps evolving thanks to AI, home monitoring and Epic integration
For years, the ECG market was relatively static. According to a new report, however, things are rapidly changing.
Safety update: New recommendations for managing patients with high-risk defibrillation leads
HRS has shared an updated guidance on managing Boston Scientific defibrillation leads at risk of experiencing a significant malfunction. The issue, first reported in July 2025, is believed to impact approximately 350,000 leads still being used today.

Universal heart screening for all athletes? Not so fast, cardiologists warn

Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences.

New heart catheter for cell therapy delivery 1 step closer to FDA approval

The BioCardia delivery catheter was designed to be used by interventional cardiologists, electrophysiologists or cardiac surgeons. It includes a tiny needle that directly engages with the patient’s cardiac tissue.

Reprocessed EP catheters recalled due to contamination risk

The FDA has announced seven Class I recalls related to this issue. Customers are urged to destroy the devices immediately instead of returning them to the manufacturer.

The HeartBeam AIMIGo device is approximately the size of a credit card and uses the company’s patented 3D vectorelectrocardiography (3D VECG) technology to capture signals from three different projections and deliver a synthesized 12-lead ECG.

ECG market keeps evolving thanks to AI, home monitoring and Epic integration

For years, the ECG market was relatively static. According to a new report, however, things are rapidly changing.

warning safety alert recall healthcare issue

Safety update: New recommendations for managing patients with high-risk defibrillation leads

HRS has shared an updated guidance on managing Boston Scientific defibrillation leads at risk of experiencing a significant malfunction. The issue, first reported in July 2025, is believed to impact approximately 350,000 leads still being used today.

Boston EP Party: Medtech companies share new electrophysiology data at AF Symposium 2026

AF Symposium 2026 in Boston included new data from some of the biggest names in electrophysiology. Johnson & Johnson MedTech, Abbott, Atraverse Medical, Field Medical, Pulse Biosciences, Argá Medtech SA and CardioFocus were just some of the medtech companies at the heart of late-breaking presentations.

New data from the Phase 3 RAPID clinical trial of etripamil, an investigational calcium channel blocker nasal spray, showed positive results in converting paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm in the at-home setting. The presentation was featured during a late-breaking clinical trials session at the American Heart Association (AHA) 2022 Scientific Sessions. #AHA22

Nasal spray for paroxysmal supraventricular tachycardia enters US market

New drug allows patients to self-treat PSVT. About 2 million people in the U.S. have been diagnosed with condition.

FDA clears AI software for heart murmur detection with digital stethoscopes

eMurmer's new Heart AI software was designed to detect both the presence and absence of heart murmurs in digital stethoscope recordings. It can also gather critical hemodynamic data, helping care teams gain a better understanding of the patient's cardiovascular health.